Pancreatic cancer immunotherapy program is to use immunotherapy drugs to activate autoimmune ability to remove cancer cells. Immunotherapy for pancreatic cancer is a brand-new treatment plan launched in recent years, which mainly involves the use of immune drugs to enhance patients’ immunity, so as to achieve the purpose of removing cancer cells and stabilizing the condition, and some of the drugs have already been applied in the clinic. Immunotherapy for pancreatic cancer mainly includes immune checkpoint inhibitors and CAR-T: 1. PD-1 antibody, PD-L1 antibody and CTLA-4 antibody belong to immune checkpoint inhibitors, such as nabumab and pembrolizumab, etc., which are usually combined with chemotherapy for comprehensive treatment; 2. Relay immune cell therapy belongs to passive immunotherapy for tumors, which activates and expands tumor-specific or non-specific killer cells in vitro and infuses them back into the body to achieve anti-tumor effects, mainly including relay NK cell and T cell therapy, of which CAR-T belongs to one of them. CAR-T is one of these therapies, and relevant clinical studies are currently underway. In addition, there are also immunotherapy programs such as cell vaccines, lysogenic viruses, therapeutic antibodies, immunomodulators and so on. It is recommended to go to a regular hospital to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate treatment program to avoid delaying the condition. Please strictly follow the doctor’s instructions for medication, and do not use medication on your own.